TONSL

TONSL is a multi-domain scaffold protein that operates as a genome caretaker at replication forks, where it forms a stable heterodimer with MMS22L that accumulates at ssDNA generated by distressed forks or processed breaks and is required for efficient RAD51 focus formation and homologous-recombination-mediated repair (PMID:21055983, PMID:21055984, PMID:21055985, PMID:21113133). The complex is targeted to post-replicative chromatin through the TONSL ankyrin-repeat domain, which reads histone H4 unmethylated at K20 (H4K20me0), a mark restricted to newly deposited histones (PMID:27338793). Within the heterodimer the MMS22L subunit directly binds RAD51, suppresses unproductive RAD51 assembly on dsDNA, and stimulates RAD51-ssDNA nucleofilament formation and strand exchange, while the complex associates with RPA-coated ssDNA to promote fork reversal and HR-mediated restart (PMID:27797818). Recruitment of MMS22L-TONSL to ssDNA depends on the histone chaperones ASF1 and CAF-1, with DNA-PKcs-dependent ASF1A phosphorylation enhancing its loading after damage (PMID:29478807). Beyond canonical HR, TONSL-MMS22L contributes to sister chromatid cohesion via an ESCO2 recruitment pathway parallel to DSCC1-RFC (PMID:36622344), recruits FANCM and the FA core complex to drive interstrand-crosslink repair and fork traverse (PMID:41030968), and suppresses polymerase-theta-dependent tandem duplications, a function conserved across worms and plants (PMID:41896213). Hypomorphic bi-allelic loss-of-function variants in TONSL cause SPONASTRIME dysplasia, with patient cells showing fork stalling, chromosomal aberrations, and reduced RAD51 foci that are rescued by wild-type TONSL (PMID:30773277, PMID:30773278). TONSL overexpression immortalizes primary breast epithelial cells and remodels chromatin accessibility toward pro-oncogenic factors, and TONSL loss confers PARP-inhibitor sensitivity, linking the gene to tumorigenesis and synthetic-lethal vulnerability (PMID:37057595, PMID:42037569).

1. 2000 Medium

   Before any DNA-repair role was known, the gene had to be defined at the molecular level; cloning established TONSL/NFKBIL2 as a distinct ankyrin-repeat protein rather than a canonical IkappaB family member.

   Evidence cDNA cloning, genomic sequencing, and FISH mapping to chromosome 8q24.3

   PMID:11246458

   Open questions at the time

   • No functional role assigned at this stage
   • Ankyrin-repeat function uncharacterized
2. 2010 High

   The central question of what TONSL does was answered by identifying its stable partner MMS22L and placing the heterodimer at ssDNA on distressed forks, where it is required for RAD51 loading and HR repair.

   Evidence Co-IP, RNAi depletion with RAD51 foci and camptothecin sensitivity assays, immunofluorescence across three simultaneous studies plus a fourth

   PMID:21055983 PMID:21055984 PMID:21055985 PMID:21113133

   Open questions at the time

   • Mechanism of RAD51 stimulation not yet resolved
   • Mode of chromatin targeting unknown
3. 2010 Medium

   To connect the complex to chromatin machinery, AP-MS identified FACT, MCM, and histone associations, hinting that the complex acts in a replication/chromatin context.

   Evidence Mass spectrometry-based affinity purification and Co-IP in two independent studies

   PMID:21055985 PMID:21113133

   Open questions at the time

   • Direct vs indirect interactions not distinguished
   • Functional significance of FACT/MCM binding untested here
4. 2016 High

   The unresolved targeting mechanism was solved by showing the TONSL ankyrin-repeat domain reads H4K20me0, explaining how the complex is restricted to newly replicated chromatin.

   Evidence Histone peptide pulldown, ARD mutagenesis, chromatin fractionation, fork-accumulation and viability assays

   PMID:27338793

   Open questions at the time

   • Structural basis of ARD-H4K20me0 recognition not fully detailed
   • Coupling between reading and RAD51 loading unclear
5. 2016 High

   The biochemical basis of RAD51 stimulation was established by showing MMS22L directly binds RAD51, suppresses dsDNA-bound RAD51, and promotes ssDNA filament formation and fork reversal.

   Evidence In vitro strand-exchange assay with recombinant MMS22L-TONSL, Co-IP, iPOND, and HR assay with interaction mutant

   PMID:27797818

   Open questions at the time

   • TONSL subunit's catalytic contribution to filament formation not defined
   • Regulation of dsDNA suppression in vivo unclear
6. 2018 High

   How the complex reaches ssDNA was clarified by placing histone chaperones ASF1/CAF-1 upstream of its recruitment and linking DNA-PKcs phosphorylation of ASF1A to enhanced loading.

   Evidence RNAi of ASF1/CAF-1, ASF1A phospho-mutant, RAD51/RPA foci, resection and cell-cycle assays

   PMID:29478807

   Open questions at the time

   • Direct chaperone-TONSL contacts not mapped
   • Order of chaperone and H4K20me0 engagement unresolved
7. 2019 High

   The physiological and disease relevance was established by showing hypomorphic TONSL variants cause SPONASTRIME dysplasia with fork-stalling phenotypes rescued by wild-type protein, and that loss is lethal in mice and zebrafish.

   Evidence Whole-exome sequencing, WT rescue, DNA fiber and RAD51 foci assays, mouse and zebrafish knockouts in two simultaneous papers

   PMID:30773277 PMID:30773278

   Open questions at the time

   • How replication defects translate to skeletal dysplasia unclear
   • Tissue-specific requirements undefined
8. 2022 Medium

   A role beyond HR was uncovered by linking TONSL-MMS22L to sister chromatid cohesion via ESCO2 recruitment in a pathway parallel to DSCC1-RFC.

   Evidence Genome-wide CRISPR synthetic-lethality screen in DSCC1-KO cells, SCC and ESCO2 recruitment assays, epistasis

   PMID:36622344

   Open questions at the time

   • Mechanism of ESCO2 recruitment by the complex unknown
   • Single-lab finding
9. 2023 Medium

   An oncogenic dimension was identified by showing TONSL overexpression immortalizes breast epithelial cells and reshapes chromatin accessibility, with sensitivity to a TONSL-FACT inhibitor.

   Evidence Immortalization assay, ATAC-seq, in vivo tumor formation, CBL0137 sensitivity

   PMID:37057595

   Open questions at the time

   • Direct chromatin targets of TONSL in transformation undefined
   • Mechanistic link between FACT and accessibility changes unclear
10. 2025 Medium

    The complex was integrated into the Fanconi anemia ICL-repair network by showing an interdependent TONSL-MMS22L/FANCM relationship that promotes FANCD2 monoubiquitination and fork traverse.

    Evidence Co-IP, chromatin fractionation, FANCD2 ubiquitination, ICL repair and traverse assays, phospho-mutant analysis (preprint)

    PMID:41030968

    Open questions at the time

    • Not yet peer-reviewed
    • Direct vs indirect FANCM contact not fully resolved
11. 2026 High

    A conserved mutational-suppression role was demonstrated by showing TONSL loss causes polymerase-theta-dependent tandem duplications across worm and plant systems.

    Evidence C. elegans and Arabidopsis knockouts, whole-genome sequencing of TDs, epistasis with polymerase theta and Pif1

    PMID:41896213

    Open questions at the time

    • Direct molecular step at which TONSL blocks TMEJ undefined
    • Human relevance not directly tested
12. 2026 Medium

    Therapeutic vulnerability was shown by demonstrating that TONSL loss impairs RAD51 recruitment in HCC, sensitizing cells to PARP inhibitors and reducing tumor growth.

    Evidence CRISPR knockout, RAD51 foci and HR assays, PARP inhibitor sensitivity, xenograft model

    PMID:42037569

    Open questions at the time

    • Generalizability across tumor types untested
    • Single-lab finding

• How the multiple TONSL-MMS22L functions—RAD51 loading, cohesion, ICL repair, and TD suppression—are coordinated and switched at a single fork remains unresolved.
• No structural model of the full heterodimer on chromatin
• Unclear how distinct downstream pathways are partitioned
• FIGNL1 interaction remains a single low-confidence preprint observation